Passage Bio reported a net loss of $45.5 million, or $14.35 per basic and diluted share, for the year ended December 31, 2025, a reduction from $64.8 million, or $21.04 per share, in 2024. Cash and cash equivalents were $46.3 million as of December 31, 2025, with a projected cash runway through the first quarter of 2027. Research and Development (R&D) expenses decreased to $23.3 million for 2025 from $40.2 million in 2024. General and Administrative (G&A) expenses decreased to $19.9 million for 2025 from $25.0 million in 2024. The company enrolled the first three FTD-GRN patients in Cohort 3 of the upliFT-D study and treated the first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4. Passage Bio is advancing a preclinical program for Huntington's disease, with a clinical candidate selection expected in the second half of 2026. Updated interim safety and biomarker data from the upliFT-D study and regulatory feedback on FTD-GRN registrational trial design are anticipated in the first half of 2026.